Bioequivalence of two preparations of ticlopidine evaluated using a pharmacodynamic end point
J. Splawinski, J. Kuzniar, R. Kurianowicz, P. Wanczura
1 National Institute of Public Health, Warsaw, and
2 District Hospital Nr. 2 , Rzesz
DOI 10.5414/CPP43452
Abstract
Objective: To evaluate the bioequivalence of 2 ticlopidine preparations, 250 mg Iclopid tablets (Pabianickie Zaklady Farmaceutyczne, Polfa, Poland; test formulation) and 250 mg Ticlid tablets (Sanofi, France; reference formulation) using a phar-macodynamic end point, i.e the platelet aggregation test ex vivo. Subjects, materials and methods: The study was open, randomized, multiple-dose, two-period, crossover with a four-week washout interval. Volunteers were screened for sensitivity towards the platelet aggregation (ex vivo) effect of ADP (30
Author Details
Authors
Departments
- 1 National Institute of Public Health, Warsaw, and
- 2 District Hospital Nr.
- 2 , Rzesz
Address
Prof. J. Splawinski
Narodowy Instytut Zdrowia Publicznego
ul. Chelmska 30/34
00725 Warszawa, Poland
Email:
[email protected]
Citation
J. Splawinski, J. Kuzniar, R. Kurianowicz and P. Wanczura. Bioequivalence of two preparations of ticlopidine evaluated using a pharmacodynamic end point. 2005; 43: 452-456. doi: 10.5414/CPP43452.
